| pubmed-article:21076381 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21076381 | lifeskim:mentions | umls-concept:C0376387 | lld:lifeskim |
| pubmed-article:21076381 | lifeskim:mentions | umls-concept:C0022671 | lld:lifeskim |
| pubmed-article:21076381 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
| pubmed-article:21076381 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:21076381 | lifeskim:mentions | umls-concept:C0814225 | lld:lifeskim |
| pubmed-article:21076381 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:21076381 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:21076381 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:21076381 | pubmed:dateCreated | 2010-12-16 | lld:pubmed |
| pubmed-article:21076381 | pubmed:abstractText | At 1 year, belatacept was associated with similar patient/graft survival, better renal function, and an improved cardiovascular/metabolic risk profile versus cyclosporine A (CsA) in the Belatacept Evaluation of Nephroprotection and Efficacy as Firstline Immunosuppression Trial (BENEFIT) and Belatacept Evaluation of Nephroprotection and Efficacy as Firstline Immunosuppression Trial-EXTended criteria donors (BENEFIT-EXT) studies. Acute rejection was more frequent with belatacept in BENEFIT. Posttransplant lymphoproliferative disorder (PTLD)--specifically central nervous system PTLD--was observed more frequently in belatacept-treated patients. This analysis assesses outcomes from BENEFIT and BENEFIT-EXT after 2 years of treatment. | lld:pubmed |
| pubmed-article:21076381 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21076381 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21076381 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21076381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21076381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21076381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21076381 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21076381 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21076381 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:21076381 | pubmed:issn | 1534-6080 | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:LarsenChristi... | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:Vanrenterghem... | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:VincentiFlavi... | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:CampistolJose... | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:FlormanSander... | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:CharpentierBe... | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:BlockAlanA | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:KamarNassimN | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:GargPushkalP | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:GrinyóJosepJ | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:LinChen-Sheng... | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:Medina-Pestan... | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:BreshahanBarb... | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:RialMaria... | lld:pubmed |
| pubmed-article:21076381 | pubmed:author | pubmed-author:Di... | lld:pubmed |
| pubmed-article:21076381 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21076381 | pubmed:day | 27 | lld:pubmed |
| pubmed-article:21076381 | pubmed:volume | 90 | lld:pubmed |
| pubmed-article:21076381 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21076381 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21076381 | pubmed:pagination | 1528-35 | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:meshHeading | pubmed-meshheading:21076381... | lld:pubmed |
| pubmed-article:21076381 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:21076381 | pubmed:articleTitle | Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. | lld:pubmed |
| pubmed-article:21076381 | pubmed:affiliation | Emory Transplant Center and Department of Surgery, Emory University, Atlanta, GA, USA. clarsen@emory.edu | lld:pubmed |
| pubmed-article:21076381 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21076381 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
